Nuvation Bio Inc.

AI Score

0

Unlock

2.59
-0.08 (-3.00%)
At close: Jan 14, 2025, 3:59 PM
2.59
0.00%
After-hours Jan 14, 2025, 07:00 PM EST
undefined%
Bid 2.3
Market Cap 871.71M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.18
PE Ratio (ttm) -1.19
Forward PE n/a
Analyst Buy
Ask 2.8
Volume 2,747,563
Avg. Volume (20D) 2,357,398
Open 2.64
Previous Close 2.67
Day's Range 2.50 - 2.64
52-Week Range 1.43 - 4.16
Beta undefined

About NUVB

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiat...

Industry Biotechnology
Sector Healthcare
IPO Date Aug 26, 2020
Employees 203
Stock Exchange NYSE
Ticker Symbol NUVB

Analyst Forecast

According to 5 analyst ratings, the average rating for NUVB stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 170.27% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
1 week ago · Source
+14.44%
Nuvation Bio shares are trading higher after RBC C... Unlock content with Pro Subscription
5 months ago · Source
-5.36%
Nuvation Bio shares are trading lower. The company reported Q2 financial results.